La Jolla Pharmaceutical Co.(NASDAQ : LJPC)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||-0.58%||450.57||2.7%||$522.91m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.20%||212.55||1.9%||$515.41m|
|GILD||Gilead Sciences, Inc.||-2.21%||61.40||1.0%||$485.52m|
|BNGO||BioNano Genomics, Inc.||-2.89%||9.73||0.0%||$374.38m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.59%||152.75||2.0%||$371.25m|
|CRSP||CRISPR Therapeutics AG||-1.25%||125.69||0.6%||$292.02m|
|EXAS||EXACT Sciences Corp.||3.67%||136.12||18.4%||$252.07m|
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jollaâ€™s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.